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Abstract We report here that aggregated L-amyloid (AL) 1^42
promotes tau aggregation in vitro in a dose-dependent manner.
When AL-mediated aggregated tau was used as a substrate for
tau protein kinase II (TPK II), an 8-fold increase in the rate of
TPK II-mediated tau phosphorylation was observed. The extent
of TPK II-dependent tau phosphorylation increased as a function
of time and AL 1^42 concentration, and hyperphosphorylated tau
was found to be decorated with an Alzheimer’s disease-related
phosphoepitope (P-Thr-231). In HEK 293 cells co-expressing
CT-100 amyloid precursor protein and tau, the release of AL 1^
42 from these cells was impaired. Taken together, these in vitro
results suggest that AL 1^42 promotes both tau aggregation and
hyperphosphorylation. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Neuro¢brillary tangles (NFTs) and senile plaques constitute
two prominent neuropathological characteristics of Alzhei-
mer’s disease (AD) [1,2]. The main ¢brous component of all
neuro¢brillary lesions is paired helical ¢lament (PHF) which
contains predominantly the abnormally phosphorylated tau
[3^8]. Tau is a microtubule (MT)-associated protein, which
promotes MT assembly and stabilization [9,10]. It has been
hypothesized that aberrant phosphorylation of tau leads to its
dissociation from MTs and aggregation into PHF, resulting in
destabilization of MTs and the death of neurons [10,11].
Recently, it has been suggested that the brain-speci¢c tau
protein kinase II (TPK II) might play an important role in
the pathogenesis of AD [12^14].
Amyloid plaques are composed of a core of L-amyloid (AL)
peptide derived from proteolytic processing of the amyloid
precursor protein, APP [15]. The AL 1^42 peptide forms ¢brils
more readily than AL 1^40 peptide [16]. A central issue that
has not been addressed concerns why NFTs and senile
plaques invariably co-exist in the AD brain and what, if
any, relationship exists between the two.
Our previous studies [14] support the hypothesis that the
initial phosphorylation of tau by TPK II is an essential step in
the detachment of tau from MTs. These in vitro results are
consistent with the proposed role of TPK II in AD patho-
genesis [12] as well as with studies in transgenic mice over-
expressing the p25 activator protein of TPK II [13]. However,
the nature of the pathological factors involved in tau
aggregation and hyperphosphorylation in AD is elusive. To
determine whether AL can alter solubility and phosphoryla-
tion characteristics of tau, we studied the in vitro e¡ects of
aggregated AL 1^42 on tau solubility and TPK II-mediated
tau phosphorylation. Results of these studies suggest
a potential role of AL 1^42 in tau aggregation and TPK II-
mediated tau hyperphosphorylation.
2. Materials and methods
2.1. Materials
AL peptides were obtained from Bachem. The AT-180 antibody
for phosphorylated tau was from Innogenetics. The 4G5 antibody
was a monoclonal made in house and reacts with unphosphorylated
and phosphorylated tau. The anti-mouse IgG-peroxidase was from
Roche Molecular Biochemicals and the ECL reagents were from
Amersham Pharmacia Biotech. GSK-3 (tau protein kinase I;
TPK I) was obtained from New England Biolabs. Human recombi-
nant tau 1-383 isoform and recombinant TPK II were puri¢ed as
described [14]. Bovine tau was obtained from Sigma Chemical Co.
Protein concentration was determined using the BCA kit from Pierce.
Sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) was carried out according to the procedure of Laemmli [17].
2.2. Cloning, expression and puri¢cation of the truncated forms of tau
The tau construct containing the four repeat (4R) domains
of tau (244Q^390A) was cloned by inserting it in the pET 23a vector
as an NdeI/EcoRI fragment and transforming it into competent
TOP 10 cells from Invitrogen. Plasmid DNA was isolated from
the correct clone and used to transform competent BL21(DE3)
cells from Stratagene. The Escherichia coli cells were grown
to an A600 of 0.6 and induced with 1 mM IPTG for 3 h in NS-85
medium [14]. Cells were collected by centrifugation and the pellets
stored at 380‡C and used for immobilized metal a⁄nity chromato-
graphy puri¢cation as described elsewhere [14]. The tau construct
containing the N-terminal domain of tau (1M^238S) with
an octa-histidine C-terminal tag was cloned by inserting it
in-frame behind the T7 tag of the pET 23a vector as a BamHI/EcoRI
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fragment. Subcloning, expression and puri¢cation were done as for
the 4R tau.
2.3. Transfection of mammalian tissue culture cells and AL detection
HEK 293 cells (ATCC, CRL-1573) were transfected with expression
constructs using the Lipofectamine Plus reagent (Gibco/BRL). The
CT-100 was expressed from the pcDNA3.1 vector (Invitrogen); the
construct encodes amino acids 596^696 of the APP696 isoform and
uses the methionine before the beta cleavage site. Tau cDNA (1^383
isoform) vector for transfection into HEK 293 cells contained a GFP
tag at its C-terminus [18]. Cells were seeded in tissue culture plates to
a density of 70^80% con£uence. A six-well plate of cells was trans-
fected with 8 Wg of each DNA in Optimem (Gibco/BRL); Optimem
was added to a total volume of 8 ml, distributed 1 ml per well and
incubated for 4 h. The transfection medium was replaced with Dul-
becco’s modi¢ed Eagle’s medium, 10% fetal bovine serum, Na-pyru-
vate, with antibiotic/antimycotic and the cells were incubated under
normal conditions (37‡C, 5% CO2) for 48 h. The conditioned medium
was removed to polypropylene tubes and stored at 380‡C until as-
sayed. Conditioned media samples were assayed for AL by sandwich
enzyme-linked immunosorbent assay (ELISA) and immunoblotting
with antibodies 6E10 (Senetek), biotinylated Rb208 for AL 1^40,
and Rb165 for AL 1^42 (P.D. Mehta, NYS Inst.).
2.4. Tau hyperphosphorylation in the presence of AL
The ¢lter-binding assay [14] was performed by incubating 2 WM tau
with 3.6 nM TPK II for 10 min (or the time indicated) at 37‡C in a
total volume of 15 Wl containing 40 mM Tris, pH 7.5, 10 mM MgCl2,
1 mM dithiothreitol (DTT), 0.1 mg/ml bovine serum albumin and
1 WCi [Q-33P]ATP. AL peptides were added at 10U concentrations
to the assay to achieve the ¢nal concentration indicated.
Gel-shift assays were carried out by incubating 3 WM tau with 50
nM TPK II and/or 167 U/ml TPK I for the indicated time at 37‡C in
a total volume of 20 Wl containing 40 mM Tris, pH 7.5, 10 mM
MgCl2, 1 mM DTT, and 1 mM ATP. AL peptides were added at
10U concentrations to the assay to achieve the ¢nal concentration
indicated. Following incubation the samples were electrophoresed on
12% SDS^PAGE and stained with Coomassie blue R-250. For West-
ern blotting of AL-mediated hyperphosphorylated tau, AT-180 anti-
body was used at a 1:5000 dilution followed by goat anti-mouse IgG-
peroxidase used at a 1:10 000 dilution as the secondary antibody. The
blots were developed using the ECL protocol.
2.5. Tau aggregation assays
When tau aggregation was studied by SDS^PAGE, 2 WM tau was
incubated with the indicated amount of AL 1^42 for the indicated
time at 37‡C in a total volume of 100 Wl containing 40 mM Tris,
pH 7.5, 10 mM MgCl2, 1 mM DTT. AL peptides were added at
10U concentrations to the assay to achieve the ¢nal concentration
indicated. Samples were centrifuged at 12 000Ug in a microcentrifuge
for 5 min. The supernatants were removed, and the pellets washed
once with 40 mM Tris, pH 7.5, 10 mM MgCl2, 1 mM DTT and
centrifuged again. The pellets were resuspended in 100 Wl bu¡er, elec-
trophoresed on 12% SDS^PAGE next to the corresponding superna-
tant, and stained with Coomassie blue R-250. Tau bands were ana-
lyzed by densitometry. Phosphorylated tau used to study aggregation
in the presence of AL 1^42 was produced by incubating 27 WM tau in
the presence of 100 nM TPK II for 4 h at 37‡C containing 40 M Tris,
pH 7.5, 10 mM MgCl2, 1 mM DTT, and 1 mM ATP. The sample was
subsequently dialyzed into 50 mM Tris, pH 8.0, 1 mM DTT.
2.6. Scintillation proximity assay (SPA) for Tau:AL interaction
For SPA, [33P]tau was added at various concentrations to 2 WM AL
1^42 and 5 mg/ml anti-mouse PVT SPA beads (Amersham) in a total
volume of 100 Wl of 40 mM Tris, pH 7.5, 10 mM MgCl2, 1 mM DTT
for 30 min at 37‡C. The samples were centrifuged at 12 000Ug in a
microcentrifuge and counted using a Packard TriCarb liquid scintilla-
tion counter. The background counts per minute (CPM) were ob-
tained by incubating varying concentrations of [33P]tau with the
SPA beads in the absence of AL 1^42. SPA counts were plotted versus
[33P]tau concentration.
The data obtained from the SPA assay were analyzed according to
the equation shown below, a rectangular hyperbola widely employed
for analyzing solid phase-binding data [19], to determine the half-
saturating level of binding (estimated dissociation constant, KD) using
the program Prism (GraphPad),
B  BmaxL
KD  L
where B is the complex concentration (in CPM), Bmax is the maximum
complex concentration and [L] is the molar concentration of tau.
3. Results
3.1. Characterization of tau and AL peptides
The properties of AL 1^42 and tau used in this study were
established by a variety of techniques. The composition of AL
1^42 peptide was con¢rmed by mass spectrometry (MS). Fur-
ther characterization of this peptide by thio£avine T-binding
[20] and native PAGE revealed that, as expected, AL 1^42
peptide was predominantly aggregated. A non-aggregated
form of AL 1^40 was used as a control and was also charac-
terized by thio£avine T £uorescence [20]. The human tau (1^
383) construct [14] was expressed in E. coli, puri¢ed, and
characterized by MS which showed that it was devoid of
any phosphorylation.
3.2. AL-mediated tau aggregation
As shown in Fig. 1A, AL 1^42-induced tau aggregation is
instantaneous (lanes 3 and 4) under de¢ned conditions. Under
these conditions, at each time point the tau protein was found
to be in the pellet fraction along with AL 1^42 which ran at
4 kDa. A dose^response study is shown in Fig. 1B. The per-
centage of tau protein in the pellet fraction was determined by
densitometry of the SDS^PAGE (Fig. 1C). These results show
that addition of AL 1^42 to soluble tau promotes tau aggre-
gation in a dose-dependent manner.
The e¡ect of AL 1^42 on aggregation of unphosphorylated
wild-type tau was indistinguishable from TPK II phosphory-
lated tau (Fig. 1C). Since TPK II is a proline-directed kinase
and all the proline-directed phosphorylation sites for TPK II
are outside the MT-binding repeat region, it is hypothesized
that AL 1^42 exerts its e¡ect on tau by interacting with its
MT-binding repeat domains. To test this hypothesis, 4R tau
(Q244^390A) lacking the N-terminal and the C-terminal
domains and N-terminal tau (M1^238S) lacking the four
repeats and the C-terminal domain were prepared to study
the e¡ect of AL 1^42 on aggregation. AL 1^42-induced aggre-
gation of 4R tau (Q244^390A) was comparable to that
observed for the wild-type tau, while AL 1^42-induced aggre-
gation was not observed with tau that lacked the MT-binding
repeat domains (Fig. 1C). These results suggest that MT-bin-
ding repeat domains are critical for AL 1^42/tau interaction,
while the N-terminal tau domain (1M^238S) is not
essential for AL 1^42-induced tau aggregation.
Since human tau is known to exist in at least six various
isoforms and only one recombinant isoform of tau (1^383)
was used in the above studies (Fig. 1), it was of interest to
determine if the observed e¡ect of AL was tau isoform (1-383)-
speci¢c. Therefore, we also studied various untagged
bovine tau isoforms in the presence of AL 1^42. The pelleted
bovine tau isoforms were monitored by Western blot using
4G5 antibody to tau. These results showed that all various
bovine tau isoforms were insoluble in the presence of AL 1^42
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in a dose-dependent manner (data not shown). Since recombi-
nant tau (1^383) used in this work contains T7 and octa-His
a⁄nity tags, the results with bovine tau isoforms also con¢rm
that the observed aggregation of human recombinant tau is
indeed due to speci¢c interaction between tau and AL 1^42.
3.3. Direct Tau:AL interaction by SPA
In order to ¢nd a more sensitive and direct measure of the
interaction of tau with AL 1^42, we used a SPA. Due to the
fact that TPK II phosphorylated tau and unphosphorylated
tau seemed to show similar aggregation in the presence of AL
1^42 (Fig. 1C), tau was labeled using [33P]ATP and TPK II.
The subsequent [33P]tau was puri¢ed and then incubated in
the presence of AL 1^42 and SPA beads and the solution was
centrifuged. Due to the insoluble nature of the tau/AL com-
plex, the [33P]tau centrifuged into a pellet came in close prox-
imity to the pelleted SPA beads and resulted in SPA counts
(Fig. 2). The low background SPA counts seen in the absence
of AL 1^42 suggested that the SPA counts obtained were the
result of an interaction between [33P]tau and AL 1^42. By
varying the concentration of [33P]tau and keeping the concen-
tration of AL constant (2 WM), a relative KD of 108 þ 25 nM
was calculated (Fig. 2). These SPA counts were inhibited in a
dose-dependent manner when [33P]tau and unlabeled tau were
added together to SPA beads in the presence of AL 1^42 (data
not shown). In contrast, soluble tau was unable to compete
with preformed AL^[33P]tau complex, suggesting AL promotes
tau aggregation. Our results with the above two independent
techniques and using puri¢ed and well characterized tau and
AL argue against any confounding interactions of either AL
or tau with other assay components or proteins.
3.4. E¡ect of co-expression of tau and CT-100 on AL secretion
from HEK 293 cells
Recent studies show that in the absence of functional PS1,
the C-terminal fragment of APP (CT-100) is accumulated in
Golgi, endoplasmic reticulum, and lysosomes [21]. This APP
stub may be prone to aggregation and/or hydrolysis to AL 1^
42 through a non-speci¢c mechanism [22]. Also, it is known
that expression of CT-100 in HEK 293 cells results in secre-
tion of both AL 1^42 and 1^40 [23]. Fig. 3 shows the co-
expression of CT-100 with Tau-GFP in these cells prevents
secretion of both AL 1^40 and 1^42. This does not appear to
be due to lower expression of CT-100 (Fig. 3, inset) as the CT-
100 expression in the presence and absence of tau overexpres-
sion is comparable. As expected, in the tau control (cells
transfected with tau alone), no CT-100 was detected. These
cell culture studies are interpreted to mean that in a cellular
environment tau presumably interacts with AL and/or its CT-
100 precursor.
Fig. 1. A: Time course of tau aggregation in the presence of AL 1^
42. Tau (2 WM) was incubated with 60 WM AL 1^42 for the indi-
cated time and the samples centrifuged. The resultant supernatant
(S) and pellet (P) were run on SDS^PAGE and Coomassie-stained.
Lanes 1 and 2, tau incubated for 2 h; lanes 3 and 4, tau and AL 1^
42 after mixing; lanes 5 and 6, tau and AL 1^42 incubated for 15
min; lanes 7 and 8, for 30 min; lanes 9 and 10, for 1 h; lanes 11
and 12, for 2 h; lane 13, markers. B: Tau (2 WM) was incubated
with varying AL 1^42 for 30 min at 37‡C. Odd-numbered lanes in-
dicate supernatant fractions and even-numbered lanes the pellet
fractions. Lanes 1 and 2, tau; lanes 3 and 4, tau and 5 WM AL 1^
42; lanes 5 and 6, tau and 10 WM AL 1^42; lanes 7 and 8, tau and
20 WM AL 1^42; lanes 9 and 10, tau and 40 WM AL 1^42; lanes 11
and 12, tau and 60 WM AL 1^42; lane 13, markers. C: The gel
shown in B was scanned by densitometry and the percentage of tau
in the pellet was plotted versus AL 1^42 concentration. Also shown
are dose^response curves for the aggregation of TPK II phosphory-
lated tau, 4R tau and N-terminal tau in the presence of varying AL
1^42.
Fig. 2. Aggregation of [33P]tau in the presence of AL 1^42. Tau:AL
complex concentration (CPM) was plotted versus [33P]tau concentra-
tion and the data ¢tted using the equation stated in Section 2.
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3.5. E¡ect of AL on TPK II-mediated tau phosphorylation
A number of recent studies are consistent with the proposed
role of TPK II in AD pathogenesis [12,14]. Therefore, we
studied the e¡ect of AL 1^42 on TPK II-mediated phosphor-
ylation of tau by following incorporation of 33P into tau using
a ¢lter-binding assay. Fig. 4 shows a time course study dem-
onstrating that in the presence of AL 1^42 there is an about
8-fold increase in the initial rate of tau phosphorylation by
TPK II. Moreover, AL 1^42 had no stimulatory e¡ect on
mitogen-activated protein kinase or PKA phosphorylation
of tau under de¢ned conditions (data not shown).
3.6. AL-mediated TPK II phosphorylation of the AD-related
tau phosphoepitope Thr-231
In order to determine the e¡ect of AL 1^42 on the extent of
tau phosphorylation, a gel-shift assay was used to follow an
increase in tau’s apparent molecular weight following AL-in-
duced phosphorylation by TPK II. As shown in Fig. 5A, a
signi¢cant gel shift was observed in the presence of AL 1^42
(lane 5) and this e¡ect was both dose- and time-dependent (data
not shown). The control peptides, non-aggregated AL 1^40 or
25^35 peptide, had no e¡ect on tau in the gel-shift assay.
Phosphorylation of an AD-related epitope (P-Thr-231) in tau
can be detected by the AT-180 monoclonal antibody, which
almost exclusively recognizes PHFs from AD brain [24]. Fig.
5B shows that AL 1^42 stimulates phosphorylation of Thr-231
by TPK II. In contrast, AL 1^42 failed to stimulate tau phos-
phorylation of Thr-231 by TPK I (GSK-3L). The Thr-231
phosphoepitope in tau could also be generated by phosphory-
lation of tau in the presence of both TPK II and TPK I, sug-
gesting a requirement for prior TPK II-mediated tau phosphor-
ylation. Notably, a slight additive e¡ect was observed when tau
was phosphorylated by TPK II and TPK I in the presence of
AL 1^42 (Fig. 5B), suggesting that the observed hyperphos-
phorylation e¡ect is additive. Furthermore, studies with a
T231A tau mutant con¢rmed that, in wild-type tau, stimulation
of phosphorylation at Thr-231 by AL 1^42 was indeed due to
phosphorylation at this epitope (data not shown).
Relative to AL 1^42, non-aggregated AL 1^40 had very
little e¡ect on tau phosphorylation (Fig. 5A) and aggregation.
We also obtained a batch of preaggregated AL 1^40 as mea-
sured by thio£avine T £uorescence and native PAGE and
studied its e¡ect on tau phosphorylation. In contrast to
Fig. 3. Co-expression of CT-100 and tau. Tau-GFP construct [18],
or a control vector (GFP) was transfected alone or in combination
with CT-100 into HEK 293 cells. The resulting conditioned medium
was then assayed for the presence of AL peptides by sandwich ELI-
SA. AL 1^40 or AL 1^42 concentrations were plotted in pg/ml. In-
set: immunoblot of the expressed CT-100 used as a standard for
monitoring expression levels.
Fig. 4. Time course of the phosphorylation of tau by TPK II in the
presence of AL 1^42. Tau (2 WM) was incubated with or without 60
WM AL 1^42 and 3.6 nM TPK II for various times. Phosphoryla-
tion was followed by 33P incorporation using the ¢lter-binding assay
and plotted as CPM incorporated versus time. Data represent the
average of three experiments.
Fig. 5. A: Phosphorylation of tau by TPK II in the presence of AL
peptides using the gel-shift assay. Lane 1, tau; lane 2, TPK II phos-
phorylated tau; lane 3, TPK II phosphorylated tau+AL 25^35; lane
4, TPK II phosphorylated tau+non-aggregated AL 1^40; lane 5,
TPK II phosphorylated tau with AL 1^42; lane 6, TPK II phos-
phorylated tau; lane 7, unphosphorylated tau; lane 8, molecular
weight markers. B: Western blot using the AT-180 antibody for
phosphorylated Thr-231. Lane 1, unphosphorylated tau; lane 2,
TPK II phosphorylated tau; lane 3, TPK II phosphorylated tau
with AL 1^42; lane 4, TPK I phosphorylated tau; lane 5, TPK I
phosphorylated tau with AL 1^42; lane 6, TPK II and TPK I phos-
phorylated tau; lane 7, TPK II and TPK I phosphorylated tau with
AL 1^42; lane 8, unphosphorylated tau.
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non-aggregated AL 1^40, the e¡ect of aggregated AL 1^40 on
tau phosphorylation and aggregation (data not shown) was
comparable to the results obtained with aggregated AL 1^42
(Fig. 1). Taken together, our in vitro results suggest that ag-
gregation of AL 1^42 or 1^40 is essential for its e¡ect on tau
aggregation and hyperphosphorylation by TPK II.
4. Discussion
The currently dominant amyloid cascade hypothesis for AD
etiology and pathogenesis is not entirely consistent with a
number of studies [25^30]. There is experimental evidence
which suggests that TPK II might be involved in the forma-
tion of hyperphosphorylated tau-containing NFTs at an early
stage [31]. Phosphorylation of human tau by TPK II inhibits
tau’s ability to promote MT assembly and TPK II-mediated
phosphorylation of MT-associated tau results in tau’s disso-
ciation from the MTs and tubulin depolymerization [14]. Dys-
regulation of TPK II is reported to play an important role in
the pathogenesis of AD [12]. These studies are consistent with
the studies in transgenic mice overexpressing the p25 activator
protein of TPK II [13]. Thus, in vitro studies were carried out
to determine if there is a potential link between aggregated AL
1^42/1^40, TPK II, tau aggregation, and hyperphosphoryla-
tion. We have shown here that AL 1^42 promotes tau aggre-
gates and this in turn stimulates TPK II-mediated tau phos-
phorylation under de¢ned conditions. In addition, interaction
of tau with AL 1^42 results in phosphorylation of tau at Thr-
231 in the presence of TPK II (Fig. 5B) and this phosphoe-
pitope is an integral part of hyperphosphorylated tau-contain-
ing NFTs. Since we probed only with AT-180 antibody, we
cannot rule out other AD-related phosphoepitopes that might
be present in tau hyperphosphorylated in the presence of AL
1^42 and TPK II. Although the extent of tau phosphorylation
by TPK I is increased in the presence of AL 1^42, the phos-
phorylation at Thr-231 did not take place when AL 1^42 was
incubated with tau and TPK I, suggesting that the observed
stimulation of phosphorylation at Thr-231 seems to be unique
to TPK II. In the context of plaques and tangles found in the
AD brain [1,2], our present studies are intriguing because they
show that direct interaction of tau with AL stimulates tau
aggregation as well as the rate of tau phosphorylation by
TPK II.
Recent studies [32] indicate that aggregation of tau protein
may result in the earliest clinically detectable stages of demen-
tia in AD. Thus, it is conceivable that intraneuronal accumu-
lation of AL 1^42 makes an important contribution to early
dementia in AD by initiating the onset of cytoskeletal disrup-
tion and tau aggregation [33]. This would be consistent with a
recent study which suggests that AL 1^42 accelerates NFT
formation in transgenic mice [34]. Thus, initial AL :tau inter-
action may set the stage for tau dysfunction and dementia.
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